Pharmacokinetics of K117 and K127, two novel antidote candidates to treat Tabun poisoning

K. Tekes, G. Karvaly, S. Nurulain, K. Kuca, K. Musilek, E. Adeghate, Y. S. Jung, H. Kalász

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Aims: K117 and K127 are bis-pyridinium aldoximes but K117 is a bis-pyridinium bis-aldoxime while K127 has only one single aldoxime in addition to its amide substituent. Is there any difference in pharmacokinetics in these compounds that otherwise have the same chemical structure? Both K117 and K127 are developed as antidotes in acetylcholinesterase and butyrylcholinesterase poisoning in terrorist attacks or intoxication with other organophosphorous compounds. Their distributions have been scouted in the bodies of rats. Main methods: White male Wistar rats were intramuscularly injected. The animals were sacrificed, tissue samples were homogenized, and either K117 or K127 concentrations were determined using reversed-phase high-performance liquid chromatography. Key findings: Both K117 and K127 were present in all tissues that were analyzed including blood (serum), the brains, cerebrospinal fluid, the eyes, livers, kidneys, lungs and testes. Their pharmacokinetics and body distributions are similar. Significance: Either K117 or K127 meets the essential requirements for antidotes. Dose dependence and kinetics of their distribution were compared to that of other pyridinium aldoximes.

Original languageEnglish
Article number108737
JournalChemico-Biological Interactions
Publication statusPublished - Sept 1 2019


  • Butyrylcholinesterase
  • Distribution
  • HPLC
  • K117
  • K127
  • Pyridinium aldoxime

ASJC Scopus subject areas

  • Toxicology


Dive into the research topics of 'Pharmacokinetics of K117 and K127, two novel antidote candidates to treat Tabun poisoning'. Together they form a unique fingerprint.

Cite this